Healthcare
TScan Therapeutics, Inc.(TCRX)
Live Price
Offline$0.92
+2.22% today
1Y Change
-34.46%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +266.7%
- EPS Growth
- +12.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TScan Therapeutics, Inc. (TCRX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $0.92 and down 34.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +266.7%, EPS growth of +12.3%, a dividend yield of 0.0%. What stands out right now is revenue +266.7%, EPS +12.3%, free cash flow -21.9% with operating margin -1315.4% and ROIC -62.5%. Valuation sits in the middle of the pack at price/sales 6.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TCRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+266.7% vs +7.6% peer median
Operating Margin
Below sector median
-1315.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +266.7% and EPS at +12.3%, with operating margin around -1315.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +3.3% | -5.0% | -19.7% |
2026 Mar 4, 2026 | +33.3% | +4.6% | +6.5% | -4.6% |
2025 Nov 12, 2025 | +20.0% | -5.0% | -13.4% | -10.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TCRX Max Drawdown
-64.44%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TCRX and SPY.
Company Overview
TScan Therapeutics, Inc.
NASDAQ Global Market
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Leadership
- Gavin MacBeath
- IPO Date
- Jul 16, 2021
- Employees
- 200
- Street Address
- 830 Winter Street
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 399 9500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.6
- Price/Book
- 1.3
Growth
- Revenue
- +266.7%
- EPS
- +12.3%
- Free Cash Flow
- -21.9%
Profitability
- Gross Margin
- 85.6%
- Operating Margin
- -1315.4%
- Net Margin
- -1256.8%
- ROE
- -79.4%
- ROIC
- -62.5%
Balance Sheet
- Debt/Equity
- 0.76
- Current Ratio
- 8.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.